150 related articles for article (PubMed ID: 35353986)
21. Structural and biochemical consequences of NF1 associated nontruncating mutations in the Sec14-PH module of neurofibromin.
Welti S; Kühn S; D'Angelo I; Brügger B; Kaufmann D; Scheffzek K
Hum Mutat; 2011 Feb; 32(2):191-7. PubMed ID: 21089070
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
[TBL] [Abstract][Full Text] [Related]
23. Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity.
Deraredj Nadim W; Chaumont-Dubel S; Madouri F; Cobret L; De Tauzia ML; Zajdel P; Bénédetti H; Marin P; Morisset-Lopez S
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12310-12315. PubMed ID: 27791021
[TBL] [Abstract][Full Text] [Related]
24. RAS and beyond: the many faces of the neurofibromatosis type 1 protein.
Anastasaki C; Orozco P; Gutmann DH
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35188187
[TBL] [Abstract][Full Text] [Related]
25. Ras-GTP regulation is not altered in cultured melanocytes with reduced levels of neurofibromin derived from patients with neurofibromatosis 1 (NF1).
Griesser J; Kaufmann D; Eisenbarth I; Bäuerle C; Krone W
Biol Chem Hoppe Seyler; 1995 Feb; 376(2):91-101. PubMed ID: 7794530
[TBL] [Abstract][Full Text] [Related]
26. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
27. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
28. Neurofibromin Structure, Functions and Regulation.
Bergoug M; Doudeau M; Godin F; Mosrin C; Vallée B; Bénédetti H
Cells; 2020 Oct; 9(11):. PubMed ID: 33121128
[TBL] [Abstract][Full Text] [Related]
29. Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.
Isakov O; Wallis D; Evans DG; Ben-Shachar S
EBioMedicine; 2018 Oct; 36():508-516. PubMed ID: 30274822
[TBL] [Abstract][Full Text] [Related]
30. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.
Xu J; Ismat FA; Wang T; Lu MM; Antonucci N; Epstein JA
Circ Res; 2009 Jul; 105(3):304-11. PubMed ID: 19574548
[TBL] [Abstract][Full Text] [Related]
31. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
Bollag G; Clapp DW; Shih S; Adler F; Zhang YY; Thompson P; Lange BJ; Freedman MH; McCormick F; Jacks T; Shannon K
Nat Genet; 1996 Feb; 12(2):144-8. PubMed ID: 8563751
[TBL] [Abstract][Full Text] [Related]
32. [Neurofibromin - protein structure and cellular functions in the context of neurofibromatosis type I pathogenesis].
Abramowicz A; Gos M
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1331-48. PubMed ID: 26671924
[TBL] [Abstract][Full Text] [Related]
33. Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis.
Hegedus B; Yeh TH; Lee DY; Emnett RJ; Li J; Gutmann DH
Hum Mol Genet; 2008 Oct; 17(19):2956-66. PubMed ID: 18614544
[TBL] [Abstract][Full Text] [Related]
34. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer.
Rad E; Tee AR
Semin Cell Dev Biol; 2016 Apr; 52():39-46. PubMed ID: 26860753
[TBL] [Abstract][Full Text] [Related]
35. The C-terminal domains of human neurofibromin and its budding yeast homologs Ira1 and Ira2 regulate the metaphase to anaphase transition.
Luo G; Kim J; Song K
Cell Cycle; 2014; 13(17):2780-9. PubMed ID: 25486365
[TBL] [Abstract][Full Text] [Related]
36. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity.
Andersen LB; Ballester R; Marchuk DA; Chang E; Gutmann DH; Saulino AM; Camonis J; Wigler M; Collins FS
Mol Cell Biol; 1993 Jan; 13(1):487-95. PubMed ID: 8417346
[TBL] [Abstract][Full Text] [Related]
37. Alternative splicing of the neurofibromatosis type I pre-mRNA.
Barron VA; Lou H
Biosci Rep; 2012 Apr; 32(2):131-8. PubMed ID: 22115364
[TBL] [Abstract][Full Text] [Related]
38. Structural analysis of the GAP-related domain from neurofibromin and its implications.
Scheffzek K; Ahmadian MR; Wiesmüller L; Kabsch W; Stege P; Schmitz F; Wittinghofer A
EMBO J; 1998 Aug; 17(15):4313-27. PubMed ID: 9687500
[TBL] [Abstract][Full Text] [Related]
39. The GTPase-activating protein-related domain of neurofibromin interacts with MC1R and regulates pigmentation-mediated signaling in human melanocytes.
Deraredj Nadim W; Hassanaly S; Bénédetti H; Kieda C; Grillon C; Morisset-Lopez S
Biochem Biophys Res Commun; 2021 Jan; 534():758-764. PubMed ID: 33187641
[TBL] [Abstract][Full Text] [Related]
40. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
